HER3-DXd

Pipeline

Status by Indication[3][1]

Competition

Competitive Landscape

Non-Small Cell Lung CancerSolid TumorCarcinoma, Non-Small-Cell LungGastroesophageal Adenocarcinoma

449 competitors in Non-Small Cell Lung Cancer

#DrugCompanyPhaseTrials

1

Dato-Dxd

AstraZeneca

Phase 3

42

Eftilagimod Alfa

IImmutep S.A.S.

Phase 3

13

Neladalkib (NVL-655)

NNuvalent Inc.

Phase 3

14

HER3-DXd

Daiichi Sankyo

Phase 2

35

Remeron

OOrganon and Co

Preclinical

16

Valemetostat Tosylate

Daiichi Sankyo

Preclinical

17

Aqupla

Jiangsu Simcere Pharmaceutical Co., Ltd.

Preclinical

—8

Ftorafur

TThe First Affiliated Hospital with Nanjing Medical University

Preclinical

—9

Vibramycin

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Preclinical

—10

Treatment

GSK

Preclinical

1Show 27 more competitors

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Clinical

Trials by Indication[1]

Non-Small Cell Lung Cancer3 trials

U3-1402 in Metastatic or Unresectable Non-Small Cell Lung Cancer

Active, not recruiting·Daiichi Sankyo·Phase 1·NCT03260491·312 enrolled

HER3-DXd (Patritumab Deruxtecan; U3-1402) in Combination With Osimertinib in Subjects With Locally Advanced or Metastatic EGFR-mutated Non-Small Cell Lung Cancer

Active, not recruiting·Daiichi Sankyo·Phase 1·NCT04676477·246 enrolled

KEYMAKER-U01 Substudy 01G: A Phase 2, Umbrella Study With Rolling Arms of Investigational Agents in Combination With Pembrolizumab With or Without Platinum-based Chemotherapy in Treatment-Naïve Participants With Stage IV Non-small Cell Lung Cancer (NSCLC)

Recruiting·Merck & Co.·Phase 2·NCT06731907·90 enrolled

ESS1 trial

Medical Access Program for Patritumab Deruxtecan

No longer available·Daiichi Sankyo··NCT06099639

Solid Tumor1 trial

HERTHENA-PanTumor01 (U31402-277): A Phase 2, Multicenter, Multicohort, Open-Label, Proof of Concept Study of Patritumab Deruxtecan (HER3-DXd; U3-1402) in Subjects With Locally Advanced or Metastatic Solid Tumors

Recruiting·Daiichi Sankyo·Phase 2·NCT06172478·740 enrolled

Gastroesophageal Adenocarcinoma1 trial

A Phase 1/2 Open-Label, Umbrella Platform Design Study to Evaluate the Safety and Efficacy of Investigational Agents in Combination With Standard of Care Treatments as the Second-Line Treatment of Participants With Advanced/Metastatic Gastroesophageal Adenocarcinoma: Substudy 06D

Recruiting·Merck & Co.·Preclinical·NCT06445972·210 enrolled

Carcinoma, Non-Small-Cell Lung1 trial

KEYMAKER-U01 Substudy 01A: A Phase 1/2, Umbrella Study With Rolling Arms of Investigational Agents With Pembrolizumab With or Without Chemotherapy in Treatment-Naive Participants With Stage IV Non-small Cell Lung Cancer (NSCLC)

Recruiting·Merck & Co.·Preclinical·NCT04165070·450 enrolled

Details

Drug Info

Related News